Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032

The nucleic acid-based therapeutics market was valued at USD 5.32 billion in 2023. It is expected to grow at a CAGR of 13.29% during the forecast period of 2024-2032 and attain a market value of USD 16.4 billion by 2032. The patent landscape is driven by the escalating number of advancements in next-generation sequencing, cancer biomarkers, and therapeutic delivery systems. Further, innovation in non-invasive diagnostics and personalised medicine are impacting patent landscape positively.

Patent Landscape Report Coverage

This report provides a comprehensive overview of the circulating DNA/RNA patent landscape, detailing industry size, growth projections, and key technological advancements. It examines patent activity by technology and indication, with a focus on leading regions such as the US, Europe, and Asia. The report also profiles key companies, their patent portfolios, and their impact on the industry. Insights into regulatory and legal considerations, along with emerging trends, offer a thorough understanding of the sector’s dynamics and future opportunities.

Circulating DNA/ RNA Patent Outlook

• The United States leads with over 600 patents, followed by Europe with 400 patents. Asia, especially China and Japan, has around 250 patents, showing rapid advancements and government support.
• Biotech firms and academic institutions are driving innovation in the circulating DNA/RNA patent landscape through extensive patent filings. Their focus on cutting-edge sequencing technologies, biomarkers, and delivery systems is crucial for advancing non-invasive diagnostics and personalised medicine.
• The patent landscape is shaped by distinct regional advantages. The US excels due to its robust biotech infrastructure and regulatory environment, Europe benefits from extensive research collaborations and funding, while Asia’s growth is spurred by substantial government initiatives and a strong focus on biotech developments, enhancing its competitive position globally.

Circulating DNA/RNA: Introduction

Circulating DNA and RNA, found in the bloodstream, are vital biomarkers for various diagnostic applications. These fragments, released from cells into the plasma, offer non-invasive insights into a range of conditions, from cancer to genetic disorders. Their presence in the blood facilitates early disease detection, monitoring, and personalised medicine.

• Patents on advanced next-generation sequencing (NGS) technologies are revolutionising the circulating DNA/RNA landscape. These patents focus on innovations in ultra-accurate, rapid, and cost-efficient sequencing methods, enhancing the detection and analysis of circulating nucleic acids, thereby opening new avenues for non-invasive diagnostics and personalised treatment strategies.
• The surge in cancer-related patents for circulating DNA/RNA biomarkers underscores a major landscape driver. These patents detail groundbreaking biomarkers and novel detection techniques, significantly boosting the precision and early detection capabilities of liquid biopsies, transforming cancer diagnosis, monitoring, and management.
• The proliferation of patents on sophisticated delivery systems for circulating DNA/RNA therapeutics is driving landscape expansion. Patents cover state-of-the-art nanoparticle technologies and targeted delivery mechanisms that ensure stability and bioavailability of nucleic acids in the bloodstream, crucial for maximising therapeutic efficacy and minimising side effects, thus advancing personalised medicine.

These drivers collectively shape a vibrant and rapidly advancing patent landscape in the circulating DNA/RNA sector, heralding substantial innovations and broader utilisation in the coming years.

Circulating DNA/ RNA Patent Segmentation Analysis

The report provides an in-depth analysis of the patents in this field by the following segmentation:

Analysis by Technology

• Extraction and Preparation of Circulating DNA/RNA
• Detection and Analysis of these cfDNA/RNA

The patent segment is led by the detection and analysis, boasting over 450 patents filed historically and 200 currently in process. The extraction and preparation segment follows with 300 patents filed and 150 pending. This patent landscape is expected to expand further, driven by innovations in non-invasive diagnostics and personalised medicine. The focus on enhancing detection accuracy and preparation efficiency will likely continue to fuel patent activity and indiustry growth in the coming years.

Analysis by Indication

• Oncology
• Infectious Diseases
• Prenatal Diagnostics
• Nervous System
• Transplantation
• Cardiovascular

The patent segment is led by the oncology, with over 500 patents filed historically and 250 currently in process. Prenatal Diagnostics and Infectious Diseases follow, with 350 and 300 patents filed respectively. This dynamic landscape, driven by innovations in non-invasive diagnostics and personalised medicine, indicates substantial future growth and expanded applications across various medical fields.

Circulating DNA/RNA Patent Jurisdiction Analysis

The circulating DNA/RNA patent landscape is characterised by significant activity across major jurisdictions, reflecting regional strengths and focuses on biotechnology innovation and regulation.

• The patent landscape for circulating DNA/RNA technologies shows significant activity across major jurisdictions. The United States leads with over 600 patents, driven by a robust innovation ecosystem and supportive regulatory framework. The strong presence of leading biotechnology and pharmaceutical companies, along with substantial research funding, ensures continuous innovation and development in this field.
• Europe follows closely with around 400 patents, benefitting from strong collaborative networks and substantial biotech investments. Countries like Germany, the UK, and France are at the forefront, fostering innovation through extensive research initiatives and supportive government policies aimed at advancing precision medicine and non-invasive diagnostics.
• Asia, particularly China and Japan, accounts for approximately 250 patents, reflecting rapid advancements and significant government support. China's aggressive push in biotech research and Japan's established technological infrastructure contribute to the growing number of patents. Both countries focus on improving healthcare outcomes through innovative diagnostic and therapeutic solutions, ensuring a competitive edge in the global industry.

Each region faces challenges in harmonising patent laws and navigating regulatory complexities. However, ongoing efforts in international collaboration and standardisation are expected to streamline processes, fostering further innovation and growth in the circulating DNA/RNA sector globally.

Patent Profile of Key Companies

The patent landscape for circulating DNA/RNA is shaped by several key companies driving innovation and securing intellectual property. Here is an overview of their patent activities.

Nantomics (NantWorks, LLC):

Nantomics, a subsidiary of NantWorks, LLC, is a prominent player in the circulating DNA/RNA patent landscape. With a focus on precision medicine and oncology, Nantomics holds numerous patents related to the detection and analysis of circulating nucleic acids. Their innovative approaches in molecular diagnostics and personalised treatment strategies highlight their commitment to advancing cancer care through cutting-edge technology.

Genentech Inc.:

Genentech Inc., a biotechnology giant, is a key contributor to the circulating DNA/RNA patent landscape. The company has secured a significant number of patents in the areas of non-invasive diagnostics and therapeutic monitoring. Genentech's patents often emphasize advanced techniques for detecting circulating tumour DNA (ctDNA) and RNA, underscoring their dedication to improving early cancer detection and patient outcomes through innovative molecular diagnostics.

Novartis AG:

Novartis AG is another major player in the Circulating DNA/ RNA patent arena. The company's extensive patent portfolio includes numerous innovations in the preparation, detection, and analysis of circulating nucleic acids. Novartis focuses on leveraging these technologies for various therapeutic areas, including oncology, cardiovascular, and infectious diseases, demonstrating their commitment to enhancing diagnostic precision and personalised treatment options across multiple medical disciplines.

Other key players in the market include Spot Biosystems Ltd, Illumina Inc.

Key Questions Answered in the Circulating DNA/ RNA Patent Landscape Report

• What are the implications of recent patent filings in circulating DNA/RNA?
• What are the challenges and opportunities in the circulating DNA/RNA patent landscape?
• What regulatory and legal considerations are crucial in the patenting of circulating DNA/RNA technologies?
• What technological innovations have recently emerged in circulating DNA/RNA patent landscape?
• How has the patent landscape for circulating DNA/ RNA industry evolved from 2023 to 2032?
• What are the major drivers and restraints influencing the growth of patents in the circulating DNA/RNA industry?
• Which technologies are leading in patent filings for circulating DNA/RNA?
• How is the patent landscape segmented by technology and indication?
• Which regions have the highest patent activity and why?
• Who are the key players in the circulating DNA/RNA patent landscape, and what are their strategies?
• How do patents in the oncology segment compare to those in other medical fields?
• What are the future trends in circulating DNA/RNA patent filings?
• How do patents on next-generation sequencing technologies impact the ?
• What role do non-invasive diagnostics play in the patent landscape?
• How are patents on delivery systems for circulating DNA/RNA therapeutics influencing industry growth?
• What are the regional strengths and focuses in circulating DNA/RNA biotechnology innovation?
• How do international collaborations and standardisations affect the patent landscape?
• What impact does government support have on patent filings in different regions?
• How do leading companies’ patent portfolios shape the industry dynamics?
• What are the key considerations for investors in the circulating DNA/RNA industry?

Reasons to Purchase this Report

This comprehensive report provides a detailed analysis of the Circulating DNA/ RNA domain, including industry size, growth projections, and key drivers of innovation. It covers the patent landscape, highlighting major technological advancements and industry segmentation by technology and indication. Regional patent activity is examined, with insights into key jurisdictions such as the US, Europe, and Asia. Additionally, the report profiles leading companies and their patent portfolios, making it an essential resource for stakeholders aiming to understand industry dynamics and future opportunities.


This product will be delivered within 5-7 business days.